Tehran (IP) – The initiation of the intranasal spray of the 'Razi Cov Pars' vaccine in phase I clinical trial was inaugurated at Tehran's Rasoul Akram Hospital Wednesday.

Iran Press/Iran News: In an interview with Iran Press, an infectious disease specialist and the main researcher of the COV Pars vaccine, Saeed Kalantari, stated that following the injectable vaccine, more immunoglobulin is expected to be made comparing to the circulating Airborne Gravity Gradiometer (AGG), but this immunoglobulin did not build up properly in the airways and did not prevent transmission.

He noted that the vaccine stimulated and made the inhaled immunoglobulin type IGA (an antibody blood protein).

"IGA immunes a person from being colonized by a virus and breaks the transmission chain, which may help end the pandemic soon," he said.

It has been said that the vaccine has promising results, and out of the 131 volunteers who received the two injections earlier (Mar 8th, 2021), five volunteers received the inhaled vaccine (Intranasal spray) at today's press conference.

Kalantari announced that the first and second injections of the first phase were completed.

"Vaccination started on 131 volunteers in early March, and today we performed the inhaled dose for the first time", he added.

He pointed out that the volunteers had had very few side effects.

Noting that the effectiveness of the vaccine takes time to be judged, Kalantari said: "After analyzing the data, the second phase will begin in late May, and it will probably be possible to mass-produce it in September.

He expressed hope to provide society with a safe and effective vaccine.


Read More:

Iran to vaccinate citizens next month with local products: Health Min.